Trial Profile

A phase I/II study of TG 4050 for treatment of head and neck cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Apr 2024 According to a Transgene media release, Phase II part of the trial to start enrolling patients in coming weeks.
05 Mar 2024 According to Transgene media release, Transgene, NEC Corporation and BostonGene Corporation announced the expansion of their collaboration for the randomized Phase I/II trial of TG4050, for patients with head and neck cancers, to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services. The partnership with BostonGene will enable fast turnaround of next-generation sequencing (NGS) data.
20 Sep 2023 According to Transgene media release, company will plan to commence a randomized Phase II trial in head and neck cancer with TG4050 in 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com